HOUSTON, May 24, 2022
/PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ:
CNSP) ("CNS" or the "Company"), a biopharmaceutical company
specializing in the development of novel treatments for primary and
metastatic cancers in the brain and central nervous system, today
announced that John Climaco, Chief
Executive Officer of CNS Pharmaceuticals, will be participating at
the H.C. Wainwright Global Investment Conference being held
May 23-26, 2022 in Miami, FL and virtually.
A video webcast of Mr. Climaco's presentation is now accessible
for viewing on-demand for those registered for the event and will
be available on the Events page in the Investors section of the
Company's website (www.cnspharma.com). The webcast replay will be
archived for 90 days following the event.
In addition to the presentation, management will be available to
participate in virtual one-on-one meetings with qualified members
of the investor community who are registered to attend the
conference. For more information, please visit the conference
website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244 drug technology portfolio, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-presentation-at-the-hc-wainwright-global-investment-conference-301553649.html
SOURCE CNS Pharmaceuticals, Inc.